Blog

  • Novartis Avidity Biosciences in talks

    Novartis Avidity Biosciences in talks

    Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. 

    Bloomberg | Bloomberg | Getty Images

    Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.

    A deal could be announced as early as Sunday, the report said.

    Novartis and Avidity didn’t immediately respond to CNBC’s requests for comment.

    Avidity specializes in developing an innovative class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates. RNA-based therapeutics are a relatively new class of medications that work by altering how genes are expressed to treat or prevent diseases.

    The reported discussions come as Novartis ramps up its research and development division. The company earlier this year pledged to invest $23 billion to build out its U.S.-based infrastructure, which includes plans to construct a second R&D hub in San Diego.

    The company has also struck two key deals with Anthos Therapeutics and Regulus Therapeutics this year to boost its development and manufacturing of cardiovascular and kidney disease drugs.

    Avidity shares closed at $49.15 on Friday. The stock, which has a market capitalization of roughly $7.2 billion, is up nearly 70% since the beginning of the year. Novartis shares closed at $130.36 on Friday.

    Read the complete Bloomberg News report here.

    Continue Reading

  • Radiohead’s Thom Yorke says he won’t play Israel under Netanyahu, but slams BDS movement

    Radiohead’s Thom Yorke says he won’t play Israel under Netanyahu, but slams BDS movement

    Radiohead frontman Thom Yorke told the UK’s Sunday Times that he won’t play in Israel again while Prime Minister Benjamin Netanyahu is in power, and that Israel should not be part of Eurovision, while also criticizing pro-Palestinian…

    Continue Reading

  • Fonseca's rise continues, wins biggest career title in Basel – ATP Tour

    1. Fonseca’s rise continues, wins biggest career title in Basel  ATP Tour
    2. Joao Fonseca vs Jaume Munar Preview: Head-to-Head and Prediction for Swiss Indoors Basel 2025  PFSN
    3. Tennis, ATP – Swiss Indoors 2025: Davidovich Fokina takes out Humbert  

    Continue Reading

  • Nigeria refinery aims to be world’s biggest with expansion

    Nigeria refinery aims to be world’s biggest with expansion

    “We are more than doubling the barrels (per day)… to 1.4 million from 650,000,” said Aliko Dangote, a Nigerian businessman who is Africa’s richest person.

    “This will make it the largest refinery” globally, surpassing India’s Jamnagar Refinery, he told a news conference in Lagos.

    The privately run Dangote refinery, which started operations last year, is a gamechanger for Nigeria, which previously had to import almost all its petrol despite being a major oil producer.

    After years of neglect and mismanagement of public refineries, Dangote has shaken up the corruption-marred players in Nigeria and driven down prices of petrol for consumers.

    “This expansion reflects our confidence in Nigeria’s future, our belief in Africa’s potential and our commitment to building energy independence for our continent,” and reduce import dependence, Dangote said, adding there was “quite a lot of demand” from west Africa and east Africa.

    Dangote also exports aviation fuel, mainly to the United States, Europe and Brazil.

    The Dangote refinery, which has sparked monopoly fears as it becomes a powerful player itself, plans to list on the Nigerian Stock Exchange next year.

    “That is a step towards broader ownership and market transparency,” said Dangote.

    A second privately owned refinery, BUA, is under construction by another Nigerian billionaire, Abdulsamad Rabiu.

    Recent strikes

    Recent moves by the Dangote refinery to bring its own, natural gas-powered trucks to distribute petrol in the country in September sparked a strike by a fuel tanker drivers’ union, which accused the company of hiring new drivers on the condition they didn’t join a union.

    The refinery denied the allegations.

    The refinery suffered a two-day strike that ended October 1 after government mediation.

    The PENGASSAN oil and gas workers’ union accused the refinery of firing 800 local workers because they unionised, and replacing them with 2,000 workers from India.

    The refinery called the allegation false, and said it had fired an unspecified number of workers over “acts of sabotage”.

    Dangote on Sunday thanked the federal government for its role “in mediating our recent disruptions at the (refinery), linked to union activities and some sabotage attempts”.

    Nigeria pumps an average of 1.5 million barrels of oil per day, according to OPEC, but it is still short of its two million bpd target.

    Continue Reading

  • Wan 2.5 vs. Wan 2.2: Inside the Next Leap of AI Video Generation on WanVideo.co

    Wan 2.5 vs. Wan 2.2: Inside the Next Leap of AI Video Generation on WanVideo.co

    The rapid evolution of AI video generation has reshaped how creators, educators, and marketers produce visual content. In this fast-moving landscape, models like Wan 2.2 laid the foundation for prompt-based video creation —…

    Continue Reading

  • Radiohead’s Thom Yorke says would not now play in Israel

    Radiohead’s Thom Yorke says would not now play in Israel

    Radiohead frontman Thom Yorke has said in a British newspaper interview he would not now perform in Israel, eight years after the band defied pro-Palestinian activists to play a Tel Aviv gig.

    “Absolutely not. I wouldn’t want to be 5,000 miles…

    Continue Reading

  • Can AMD’s Rally Continue After a 58.6% Surge in the Past Month?

    Can AMD’s Rally Continue After a 58.6% Surge in the Past Month?

    If you are trying to decide what to do with Advanced Micro Devices stock, you are definitely not alone right now. The past few months have been a wild ride for AMD, giving investors plenty to cheer about. After a steady upward climb, the stock closed at $252.92, with a stunning 109.7% gain year-to-date and an eye-popping 58.6% pop just in the last month. That sort of momentum naturally has everyone wondering: is there more room to run, or is this as good as it gets?

    Much of this excitement traces back to the growing market buzz around AI computing, where AMD has been grabbing headlines thanks to both its latest hardware launches and fresh partnerships with big players in cloud infrastructure. Though the AI story is driving a lot of expectations, the market seems to be constantly re-evaluating AMD’s competitive positioning and its ability to keep growing as more players rush in. Notably, the 8.5% gain over the past week hints at renewed confidence in the company’s prospects compared to rivals.

    But hype alone does not tell the full story. If you are trying to make a level-headed decision, valuations matter. Looking under the hood, AMD’s current value score sits at 2 out of 6, meaning the stock is flagged as undervalued in just two checks out of the six most common methods. That is neither a screaming deal nor a red flag; instead, it calls for a deeper look at how AMD stacks up across key metrics.

    Let’s dig into those valuation approaches and see what each can (and cannot) reveal, because as you will see, there is an even better way to make sense of AMD’s worth that many investors overlook.

    Advanced Micro Devices scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future free cash flows and discounting them back to today’s dollars. This approach gives investors a sense of what the business is fundamentally worth based on its ability to generate cash over time.

    For Advanced Micro Devices, the DCF model starts with its latest reported Free Cash Flow of $4.1 Billion. Analyst estimates provide projections out to 2029, forecasting that AMD could generate as much as $18.7 Billion in free cash flow by that year. After five years, additional annual projections are extended through 2035, all converted into today’s terms using a required rate of return.

    Based on these assumptions and projections, the estimated DCF fair value for AMD is $165.73 per share. With the current share price at $252.92, this model implies the stock is trading at about a 52.6% premium to its intrinsic value. This suggests AMD appears substantially overvalued based on this cash flow methodology, even when factoring in robust long-term growth.

    Result: OVERVALUED

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Advanced Micro Devices.

    AMD Discounted Cash Flow as at Oct 2025

    Our Discounted Cash Flow (DCF) analysis suggests Advanced Micro Devices may be overvalued by 52.6%. Find undervalued stocks or create your own screener to find better value opportunities.

    For growing and profitable companies like Advanced Micro Devices, the Price-to-Sales (P/S) ratio is often a preferred way to assess valuation. This metric is especially useful when companies are reinvesting heavily for growth, and it helps investors gauge how the market values each dollar of revenue generated.

    The “right” P/S ratio for a company depends on several factors, notably its future growth outlook and the risks it faces. Higher expected growth or lower risk typically support a higher multiple, while lower growth or more uncertainty would warrant a lower ratio. Investors also compare this metric to industry averages and direct peers for further context.

    Currently, AMD trades at a P/S of 13.87x. This sits slightly below the average of its peers at 14.51x, but well above the broader semiconductor industry average of 5.28x. Simply Wall St’s proprietary Fair Ratio for AMD, calculated using an algorithm that factors in the company’s growth rate, profit margin, size, risk profile and its specific competitive landscape, is 17.95x. Unlike industry or peer averages, the Fair Ratio gives a more tailored sense of what a “normal” valuation should be for AMD specifically, rather than lumping it in with companies that might have very different prospects or risks.

    Given that AMD’s actual P/S ratio of 13.87x is noticeably below its Fair Ratio of 17.95x, this suggests there is still value in the stock at current levels, even at a premium to the industry. AMD may be undervalued by this approach, considering its strong outlook and fundamentals.

    Result: UNDERVALUED

    NasdaqGS:AMD PS Ratio as at Oct 2025
    NasdaqGS:AMD PS Ratio as at Oct 2025

    PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

    Earlier, we mentioned there is an even better way to understand valuation. Let’s introduce you to Narratives, a dynamic approach that brings your unique perspective to investment decisions by combining a company’s story with your own financial forecasts.

    A Narrative is more than just numbers on a page. It is your personal thesis about Advanced Micro Devices, where you express why you think the company will outperform (or underperform) and how your assumptions about future revenue, margins, and fair value shape your outlook.

    Instead of relying solely on static data or generic ratios, Narratives link a company’s journey, including key business drivers, risks, and opportunities, to the numbers in a concrete forecast, which then outputs an estimated fair value. This method is simple, accessible, and built into Simply Wall St’s Community page, where millions of investors worldwide compare Narratives and revise them as fresh news or earnings are released.

    With Narratives, you get a clear, side-by-side view of when AMD’s price is below, above, or right in line with your own fair value, helping you decide when to buy, hold, or sell. In addition, these projections update automatically as new developments unfold, so you always have the latest story.

    For example, some AMD Narratives forecast a fair value as low as $136 per share, focused on margin pressures and export risks, while others see over $230 per share, emphasizing accelerating AI deals and long-term market share gains.

    For Advanced Micro Devices, here are previews of two leading Advanced Micro Devices narratives:

    🐂 Advanced Micro Devices Bull Case

    Fair Value: $290.64

    Current Price is approximately 13% below this narrative’s fair value

    Forecast Revenue Growth: 31%

    • Projects AMD’s explosive revenue and margin growth, driven by aggressive expansion in AI and efficiency improvements led by CEO Lisa Su.

    • Expects new product launches in 2026 to accelerate performance, targeting AMD stock in the $200 to $300 range within 2 to 3 years and above $500 over 10 years.

    • Highlights AMD’s improving profit ratios and consistent revenue growth, viewing margin and operational gains as the primary value drivers.

    🐻 Advanced Micro Devices Bear Case

    Fair Value: $180.10

    Current Price is approximately 40% above this narrative’s fair value

    Forecast Revenue Growth: 16.5%

    • Credits AMD’s strong CPU and GPU innovation, but sees limited upside due to heavy competition from Nvidia, supply chain risks, and gaming segment volatility.

    • Identifies Data Center and Client segment momentum but forecasts more modest, cyclical growth rates and views Embedded and Gaming as near-term weak spots.

    • Values AMD’s market share gains but considers current pricing overextended relative to achievable near-term profit growth.

    Do you think there’s more to the story for Advanced Micro Devices? Create your own Narrative to let the Community know!

    NasdaqGS:AMD Community Fair Values as at Oct 2025
    NasdaqGS:AMD Community Fair Values as at Oct 2025

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AMD.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear

    Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear

    Cytokines are believed to play a key role in treatment resistance in patients with ovarian cancer, according to a new review article published in the International Journal of Cancer, but the exact role and mechanisms behind it have remained…

    Continue Reading

  • This Common Organism Could Survive on Mars – SciTechDaily

    1. This Common Organism Could Survive on Mars  SciTechDaily
    2. Baker’s yeast has the resilience to withstand Martian environment: Study  The Hindu
    3. IISc study suggests yeast could be first Earth organism to live on Mars  Moneycontrol
    4. Survival of the…

    Continue Reading

  • The next iPad Pro could be the first to get vapor chamber cooling

    The next iPad Pro could be the first to get vapor chamber cooling

    The iterative upgrades for iPads may not be enticing enough to warrant a new purchase every year, but Apple may have a particularly cool upgrade to convince users to shell out for the next iPad Pro. According to Bloomberg‘s Mark Gurman, Apple is…

    Continue Reading